ImmunoVaccine Technologies (IVT) has signed an agreement with UK-based Scancell. The research agreement will explore the potential of using IVT’s DepoVax delivery system for Scancell’s novel ImmunoBody DNA vaccines.
Marc Mansour, vice president of R&D at IVT, said: Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration. Our DepoVax technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques.
David Evans, chairman of Scancell, said: IVT’s DepoVax represents a potentially attractive future delivery system for our ImmunoBody DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable.
DepoVax is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax enhances the immunogenicity of antigens in general, and can be used to dramatically enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes.